Clinical Observation of Ezetimibe Combined with Simvastatin in the Treatment of Membranous Nephropathy Complicated with Hyperlipidemia
10.6039/j.issn.1001-0408.2016.23.36
- VernacularTitle:依折麦布联合辛伐他汀治疗膜性肾病合并高脂血症的临床观察
- Author:
Xiaomin ZHANG
;
Fuan WANG
;
Yu ZHANG
;
Xianchao ZHANG
- Publication Type:Journal Article
- Keywords:
Membranous nephropathy;
Hyperlipidemia;
Ezetimibe;
Simvastation;
Drug combination;
Efficacy;
Lipid
- From:
China Pharmacy
2016;27(23):3273-3275
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy and safety of ezetimibe combined with simvastatin in the treatment of membranous nephropathy complicated with hyperlipidemia. METHODS:90 patients with membranous nephropathy complicated with hyperlipidemia were randomly divided into observation group and control group,45 cases in each group. All patients received health guidance,low-fat diet,and the drugs without interfere with regulating lipid,hepatoprotective and lipid metabolism were for-bid. Control group was orally given 20 mg Simvastatin tablet,qd;observation group was additionally given 10 mg Ezetimibe tab-let,qd. They were treated for 8 weeks. Clinical efficacy was observed,lipid levels [total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol (HDL-C)],aspartate aminotransferase (AST),ala-nine aminotransferase(ALT),urinary protein quatitation,creatine kinase(CK)before and 2,4,8 weeks after treatment,and the incidence of adverse reactions were compared. RESULTS:Total effective rates of membranous nephropathy and hyperlipidemia were 95.56% and 93.30% in observation group,which were significantly higher than 73.33% and 75.56% in control graup,with statistical significance (P<0.05) .There were no significant differences in TG,HDL-C and LDL-C levels before and 2,4,8 weeks after treatment,and TC level before and 2,4 weeks after treatment between 2 groups (P>0.05);after 8 weeks of treat-ment,TC level in observation group was significantly lower than control group,the differences were statistically significant (P<0.05). Compared with control group,there were no significant differences in AST,ALT,urinary protein quatitation and CK level between 2 groups before and 2,4,8 weeks after treatment(P>0.05). And there was no significant difference in the incidence of adverse reactions between 2 groups(P>0.05). CONCLUSIONS:Ezetimibe shows similar clinical efficacy with simvastatin in the treatment of membranous nephropathy complicated with hyperlipidemia,it can effectively reduce TC level,with good safety.
